Bioxytran Inc (BIXT)

[Ecomike]

You folks need to read this. This could set a fire under $BIXT

Only 2 perfect clinical trials in the past decade

https://www.linkedin.com/pulse/mythbusting-quest-perfect-clinical-trial-michael-sheikh/

"When we at Bioxytran got our clinical trial results back I was astounded because I had never seen a perfect clinical trial in all my years in biotech. Being the diligent researcher that I am, I tried to find one but none of the search terms yielded any fruit. Then I narrowed the search looking for a 100% response rate. I found it, the other perfect clinical trial this past decade."

"Gilead Sciences purchased Pharmasset for $11.0 billion to get their at-the-time promising Phase 3 ready Hepatitis C (HCV) asset in 2011. They had a perfect 21/21 response rate for sustained virological response 12 weeks after treatment (SVR12)."

"Now, this was an open-label trial with no control, but the endpoint was SVR12 which is a proxy for the complete elimination of the virus. They enrolled 100 participants separated out by the severity of HCV; some had never had treatment and others had failed the standard of care. Across the board the results were phenomenal and two of the five cohorts had a perfect score."

"Gilead’s HCV drug is now known as Harvoni, and many refer to it as a cure for Hepatitis C as it was extremely efficacious across HCV genotypes, referred to as pan-genotypic. Harvoni (sofosbuvir) interferes with two proteins involved in the viral life cycle, preventing the replication of virions. The treatment uses sofosbuvir which is an NS5B inhibitor and a second molecule called ledipasivir which is a NS5A inhibitor. The Mechanism of Action (MOA) of these antiviral is through protease inhibition which stops the viral replication. Ledipasvir is an inhibitor of the HCV NS5A protein, which is a non-enzymatic, nonstructural protein required for viral replication. Sofosbuvir, on the other hand, is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which helps make new RNA for the new virions."

The rest of the article is on that link on LinkedIn